Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 112

1.

MRI liver fat quantification in an oncologic population: the added value of complex chemical shift-encoded MRI.

Corrias G, Krebs S, Eskreis-Winkler S, Ryan D, Zheng J, Capanu M, Saba L, Monti S, Fung M, Reeder S, Mannelli L.

Clin Imaging. 2018 Aug 8;52:193-199. doi: 10.1016/j.clinimag.2018.08.002. [Epub ahead of print]

PMID:
30103108
2.

Phase II study of trastuzumab with modified docetaxel, cisplatin, and 5 fluorouracil in metastatic HER2-positive gastric cancer.

Mondaca S, Margolis M, Sanchez-Vega F, Jonsson P, Riches JC, Ku GY, Hechtman JF, Tuvy Y, Berger MF, Shah MA, Kelsen DP, Ilson DH, Yu K, Goldberg Z, Epstein AS, Desai A, Chung V, Chou JF, Capanu M, Solit DB, Schultz N, Janjigian YY.

Gastric Cancer. 2018 Aug 7. doi: 10.1007/s10120-018-0861-7. [Epub ahead of print]

PMID:
30088161
3.

Temporal changes in MRI appearance of the prostate after focal ablation.

Hötker AM, Meier A, Mazaheri Y, Zheng J, Capanu M, Chaim J, Sosa R, Coleman J, Hricak H, Akin O.

Abdom Radiol (NY). 2018 Aug 1. doi: 10.1007/s00261-018-1715-9. [Epub ahead of print]

PMID:
30069583
4.

Pancreatic adenocarcinoma: insights into patterns of recurrence and disease behavior.

Sahin IH, Elias H, Chou JF, Capanu M, O'Reilly EM.

BMC Cancer. 2018 Jul 28;18(1):769. doi: 10.1186/s12885-018-4679-9.

5.

CT features of HER2-mutant lung adenocarcinomas.

Sawan P, Plodkowski AJ, Li AE, Li BT, Drilon A, Capanu M, Ginsberg MS.

Clin Imaging. 2018 Sep - Oct;51:279-283. doi: 10.1016/j.clinimag.2018.05.028. Epub 2018 Jun 7. Review.

6.

Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention.

Lowery MA, Ptashkin R, Jordan E, Berger MF, Zehir A, Capanu M, Kemeny NE, O'Reilly EM, El-Dika I, Jarnagin WR, Harding JJ, D'Angelica MI, Cercek A, Hechtman JF, Solit DB, Schultz N, Hyman DM, Klimstra DS, Saltz LB, Abou-Alfa GK.

Clin Cancer Res. 2018 Sep 1;24(17):4154-4161. doi: 10.1158/1078-0432.CCR-18-0078. Epub 2018 May 30.

PMID:
29848569
7.

Rates of TP53 Mutation are Significantly Elevated in African American Patients with Gastric Cancer.

van Beek EJAH, Hernandez JM, Goldman DA, Davis JL, McLaughlin K, Ripley RT, Kim TS, Tang LH, Hechtman JF, Zheng J, Capanu M, Schultz N, Hyman DM, Ladanyi M, Berger MF, Solit DB, Janjigian YY, Strong VE.

Ann Surg Oncol. 2018 Jul;25(7):2027-2033. doi: 10.1245/s10434-018-6502-x. Epub 2018 May 3.

PMID:
29725898
8.

Breast Cancer Family History and Contralateral Breast Cancer Risk in Young Women: An Update From the Women's Environmental Cancer and Radiation Epidemiology Study.

Reiner AS, Sisti J, John EM, Lynch CF, Brooks JD, Mellemkjær L, Boice JD, Knight JA, Concannon P, Capanu M, Tischkowitz M, Robson M, Liang X, Woods M, Conti DV, Duggan D, Shore R, Stram DO, Thomas DC, Malone KE, Bernstein L; WECARE Study Collaborative Group, Bernstein JL.

J Clin Oncol. 2018 May 20;36(15):1513-1520. doi: 10.1200/JCO.2017.77.3424. Epub 2018 Apr 5.

PMID:
29620998
9.

Malignant Pleural Mesothelioma: Are There Imaging Characteristics Associated With Different Histologic Subtypes on Computed Tomography?

Escalon JG, Harrington KA, Plodkowski AJ, Zheng J, Capanu M, Zauderer MG, Rusch VW, Ginsberg MS.

J Comput Assist Tomogr. 2018 Jul/Aug;42(4):601-606. doi: 10.1097/RCT.0000000000000727.

PMID:
29613986
10.

Adrenal Metastasectomy in the Presence and Absence of Extraadrenal Metastatic Disease.

Russo AE, Untch BR, Kris MG, Chou JF, Capanu M, Coit DG, Chaft JE, D'Angelica MI, Brennan MF, Strong VE.

Ann Surg. 2018 Mar 23. doi: 10.1097/SLA.0000000000002749. [Epub ahead of print]

PMID:
29578911
11.

What CT characteristics of lepidic predominant pattern lung adenocarcinomas correlate with invasiveness on pathology?

Aherne EA, Plodkowski AJ, Montecalvo J, Hayan S, Zheng J, Capanu M, Adusumilli PS, Travis WD, Ginsberg MS.

Lung Cancer. 2018 Apr;118:83-89. doi: 10.1016/j.lungcan.2018.01.013. Epub 2018 Feb 3.

PMID:
29572008
12.

MR Imaging of Rectal Cancer: Radiomics Analysis to Assess Treatment Response after Neoadjuvant Therapy.

Horvat N, Veeraraghavan H, Khan M, Blazic I, Zheng J, Capanu M, Sala E, Garcia-Aguilar J, Gollub MJ, Petkovska I.

Radiology. 2018 Jun;287(3):833-843. doi: 10.1148/radiol.2018172300. Epub 2018 Mar 7.

PMID:
29514017
13.

Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms.

Lowery MA, Wong W, Jordan EJ, Lee JW, Kemel Y, Vijai J, Mandelker D, Zehir A, Capanu M, Salo-Mullen E, Arnold AG, Yu KH, Varghese AM, Kelsen DP, Brenner R, Kaufmann E, Ravichandran V, Mukherjee S, Berger MF, Hyman DM, Klimstra DS, Abou-Alfa GK, Tjan C, Covington C, Maynard H, Allen PJ, Askan G, Leach SD, Iacobuzio-Donahue CA, Robson ME, Offit K, Stadler ZK, O'Reilly EM.

J Natl Cancer Inst. 2018 Feb 28. doi: 10.1093/jnci/djy024. [Epub ahead of print]

PMID:
29506128
14.

Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations.

Hu ZI, Shia J, Stadler ZK, Varghese AM, Capanu M, Salo-Mullen E, Lowery MA, Diaz LA Jr, Mandelker D, Yu KH, Zervoudakis A, Kelsen DP, Iacobuzio-Donahue CA, Klimstra DS, Saltz LB, Sahin IH, O'Reilly EM.

Clin Cancer Res. 2018 Mar 15;24(6):1326-1336. doi: 10.1158/1078-0432.CCR-17-3099. Epub 2018 Jan 24.

PMID:
29367431
15.

Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma.

O'Reilly EM, Lee JW, Lowery MA, Capanu M, Stadler ZK, Moore MJ, Dhani N, Kindler HL, Estrella H, Maynard H, Golan T, Segal A, Salo-Mullen EE, Yu KH, Epstein AS, Segal M, Brenner R, Do RK, Chen AP, Tang LH, Kelsen DP.

Cancer. 2018 Apr 1;124(7):1374-1382. doi: 10.1002/cncr.31218. Epub 2018 Jan 16.

PMID:
29338080
16.

Frequency, Morbidity, and Mortality of Bone Metastases in Advanced Hepatocellular Carcinoma.

Harding JJ, Abu-Zeinah G, Chou JF, Owen DH, Ly M, Lowery MA, Capanu M, Do R, Kemeny NE, O'Reilly EM, Saltz LB, Abou-Alfa GK.

J Natl Compr Canc Netw. 2018 Jan;16(1):50-58. doi: 10.6004/jnccn.2017.7024.

PMID:
29295881
17.

Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma.

Lowery MA, Kelsen DP, Capanu M, Smith SC, Lee JW, Stadler ZK, Moore MJ, Kindler HL, Golan T, Segal A, Maynard H, Hollywood E, Moynahan M, Salo-Mullen EE, Do RKG, Chen AP, Yu KH, Tang LH, O'Reilly EM.

Eur J Cancer. 2018 Jan;89:19-26. doi: 10.1016/j.ejca.2017.11.004. Epub 2017 Dec 8.

PMID:
29223478
18.

Prospective phase II trial of combination hepatic artery infusion and systemic chemotherapy for unresectable colorectal liver metastases: Long term results and curative potential.

Pak LM, Kemeny NE, Capanu M, Chou JF, Boucher T, Cercek A, Balachandran VP, Kingham TP, Allen PJ, DeMatteo RP, Jarnagin WR, D'Angelica MI.

J Surg Oncol. 2018 Mar;117(4):634-643. doi: 10.1002/jso.24898. Epub 2017 Nov 22.

PMID:
29165816
19.

Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer.

Janjigian YY, Sanchez-Vega F, Jonsson P, Chatila WK, Hechtman JF, Ku GY, Riches JC, Tuvy Y, Kundra R, Bouvier N, Vakiani E, Gao J, Heins ZJ, Gross BE, Kelsen DP, Zhang L, Strong VE, Schattner M, Gerdes H, Coit DG, Bains M, Stadler ZK, Rusch VW, Jones DR, Molena D, Shia J, Robson ME, Capanu M, Middha S, Zehir A, Hyman DM, Scaltriti M, Ladanyi M, Rosen N, Ilson DH, Berger MF, Tang L, Taylor BS, Solit DB, Schultz N.

Cancer Discov. 2018 Jan;8(1):49-58. doi: 10.1158/2159-8290.CD-17-0787. Epub 2017 Nov 9.

PMID:
29122777
20.

Clinical and molecular characterization of patients with cancer of unknown primary in the modern era.

Varghese AM, Arora A, Capanu M, Camacho N, Won HH, Zehir A, Gao J, Chakravarty D, Schultz N, Klimstra DS, Ladanyi M, Hyman DM, Solit DB, Berger MF, Saltz LB.

Ann Oncol. 2017 Dec 1;28(12):3015-3021. doi: 10.1093/annonc/mdx545.

PMID:
29045506
21.

A phase 1/1B trial of ADI-PEG 20 plus nab-paclitaxel and gemcitabine in patients with advanced pancreatic adenocarcinoma.

Lowery MA, Yu KH, Kelsen DP, Harding JJ, Bomalaski JS, Glassman DC, Covington CM, Brenner R, Hollywood E, Barba A, Johnston A, Liu KC, Feng X, Capanu M, Abou-Alfa GK, O'Reilly EM.

Cancer. 2017 Dec 1;123(23):4556-4565. doi: 10.1002/cncr.30897. Epub 2017 Aug 18.

PMID:
28832976
22.

Imaging features of hepatocellular carcinoma compared to intrahepatic cholangiocarcinoma and combined tumor on MRI using liver imaging and data system (LI-RADS) version 2014.

Horvat N, Nikolovski I, Long N, Gerst S, Zheng J, Pak LM, Simpson A, Zheng J, Capanu M, Jarnagin WR, Mannelli L, Do RKG.

Abdom Radiol (NY). 2018 Jan;43(1):169-178. doi: 10.1007/s00261-017-1261-x.

PMID:
28765978
23.

O6-Methylguanine DNA Methyltransferase Status Does Not Predict Response or Resistance to Alkylating Agents in Well-Differentiated Pancreatic Neuroendocrine Tumors.

Raj N, Klimstra DS, Horvat N, Zhang L, Chou JF, Capanu M, Basturk O, Do RKG, Allen PJ, Reidy-Lagunes D.

Pancreas. 2017 Jul;46(6):758-763. doi: 10.1097/MPA.0000000000000842.

24.

A Comparison of Yttrium-90 Microsphere Radioembolization to Hepatic Arterial Infusional Chemotherapy for Patients with Chemo-refractory Hepatic Colorectal Metastases.

Cercek A, Gendel V, Jabbour S, Moore D, Chen C, Nosher J, Capanu M, Chou JF, Boucher T, Kemeny N, Carpizo DR.

Curr Treat Options Oncol. 2017 Jul;18(7):42. doi: 10.1007/s11864-017-0481-1.

PMID:
28608276
25.

Clinical Features and Outcomes of Patients with Colorectal Cancers Harboring NRAS Mutations.

Cercek A, Braghiroli MI, Chou JF, Hechtman JF, Kemeny N, Saltz L, Capanu M, Yaeger R.

Clin Cancer Res. 2017 Aug 15;23(16):4753-4760. doi: 10.1158/1078-0432.CCR-17-0400. Epub 2017 Apr 26.

26.

Renal cyst formation in patients treated with crizotinib for non-small cell lung cancer-Incidence, radiological features and clinical characteristics.

Halpenny DF, McEvoy S, Li A, Hayan S, Capanu M, Zheng J, Riely G, Ginsberg MS.

Lung Cancer. 2017 Apr;106:33-36. doi: 10.1016/j.lungcan.2017.01.010. Epub 2017 Jan 22.

27.

Phase II study of bevacizumab and preoperative chemoradiation for esophageal adenocarcinoma.

Ku GY, Bains MS, Park DJ, Janjigian YY, Rusch VW, Rizk NP, Yoon SS, Millang B, Capanu M, Goodman KA, Ilson DH.

J Gastrointest Oncol. 2016 Dec;7(6):828-837. doi: 10.21037/jgo.2016.08.09.

28.

Relevance of CEA and LDH in relation to KRAS status in patients with unresectable colorectal liver metastases.

Connell LC, Boucher TM, Chou JF, Capanu M, Maldonado S, Kemeny NE.

J Surg Oncol. 2017 Mar;115(4):480-487. doi: 10.1002/jso.24536. Epub 2016 Dec 23.

29.

Response rates of hepatic arterial infusion pump therapy in patients with metastatic colorectal cancer liver metastases refractory to all standard chemotherapies.

Cercek A, Boucher TM, Gluskin JS, Aguiló A, Chou JF, Connell LC, Capanu M, Reidy-Lagunes D, D'Angelica M, Kemeny NE.

J Surg Oncol. 2016 Nov;114(6):655-663. doi: 10.1002/jso.24399. Epub 2016 Aug 26.

30.

Treatment Response and Outcomes of Grade 3 Pancreatic Neuroendocrine Neoplasms Based on Morphology: Well Differentiated Versus Poorly Differentiated.

Raj N, Valentino E, Capanu M, Tang LH, Basturk O, Untch BR, Allen PJ, Klimstra DS, Reidy-Lagunes D.

Pancreas. 2017 Mar;46(3):296-301. doi: 10.1097/MPA.0000000000000735.

31.

Use of positron emission tomography scan response to guide treatment change for locally advanced gastric cancer: the Memorial Sloan Kettering Cancer Center experience.

Won E, Shah MA, Schöder H, Strong VE, Coit DG, Brennan MF, Kelsen DP, Janjigian YY, Tang LH, Capanu M, Rizk NP, Allen PJ, Bains MS, Ilson DH.

J Gastrointest Oncol. 2016 Aug;7(4):506-14. doi: 10.21037/jgo.2016.06.01.

32.

Pancreas Adenocarcinoma: Ascites, Clinical Manifestations, and Management Implications.

Hicks AM, Chou J, Capanu M, Lowery MA, Yu KH, O'Reilly EM.

Clin Colorectal Cancer. 2016 Dec;15(4):360-368. doi: 10.1016/j.clcc.2016.04.014. Epub 2016 May 7.

33.

Change in chemotherapy during concurrent radiation followed by surgery after a suboptimal positron emission tomography response to induction chemotherapy improves outcomes for locally advanced esophageal adenocarcinoma.

Ku GY, Kriplani A, Janjigian YY, Kelsen DP, Rusch VW, Bains M, Chou J, Capanu M, Wu AJ, Goodman KA, Ilson DH.

Cancer. 2016 Jul 1;122(13):2083-90. doi: 10.1002/cncr.30028. Epub 2016 May 6.

34.

Updated long-term survival for patients with metastatic colorectal cancer treated with liver resection followed by hepatic arterial infusion and systemic chemotherapy.

Kemeny NE, Chou JF, Boucher TM, Capanu M, DeMatteo RP, Jarnagin WR, Allen PJ, Fong YC, Cercek A, D'Angelica MI.

J Surg Oncol. 2016 Apr;113(5):477-84. doi: 10.1002/jso.24189. Epub 2016 Feb 2.

35.

Patterns and Predictors of Weight Loss After Gastrectomy for Cancer.

Davis JL, Selby LV, Chou JF, Schattner M, Ilson DH, Capanu M, Brennan MF, Coit DG, Strong VE.

Ann Surg Oncol. 2016 May;23(5):1639-45. doi: 10.1245/s10434-015-5065-3. Epub 2016 Jan 5.

36.

Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium.

Shah MA, Janjigian YY, Stoller R, Shibata S, Kemeny M, Krishnamurthi S, Su YB, Ocean A, Capanu M, Mehrotra B, Ritch P, Henderson C, Kelsen DP.

J Clin Oncol. 2015 Nov 20;33(33):3874-9.

PMID:
26438119
37.

Phase II Trial of Sorafenib in Patients with Chemotherapy Refractory Metastatic Esophageal and Gastroesophageal (GE) Junction Cancer.

Janjigian YY, Vakiani E, Ku GY, Herrera JM, Tang LH, Bouvier N, Viale A, Socci ND, Capanu M, Berger M, Ilson DH.

PLoS One. 2015 Aug 14;10(8):e0134731. doi: 10.1371/journal.pone.0134731. eCollection 2015.

38.

Treatment, Outcomes, and Clinical Trial Participation in Elderly Patients With Metastatic Pancreas Adenocarcinoma.

Li D, Capanu M, Yu KH, Lowery MA, Kelsen DP, O'Reilly EM.

Clin Colorectal Cancer. 2015 Dec;14(4):269-76.e1. doi: 10.1016/j.clcc.2015.05.005. Epub 2015 May 22.

39.

Integrative analysis of functional genomic annotations and sequencing data to identify rare causal variants via hierarchical modeling.

Capanu M, Ionita-Laza I.

Front Genet. 2015 May 8;6:17. doi: 10.3389/fgene.2015.00176. eCollection 2015.

40.

Pretreatment Neutrophil to Lymphocyte Ratio Independently Predicts Disease-specific Survival in Resectable Gastroesophageal Junction and Gastric Adenocarcinoma.

Wang SC, Chou JF, Strong VE, Brennan MF, Capanu M, Coit DG.

Ann Surg. 2016 Feb;263(2):292-7. doi: 10.1097/SLA.0000000000001189.

41.

Laparoscopic Versus Open Gastrectomy for Gastric Adenocarcinoma in the West: A Case-Control Study.

Kelly KJ, Selby L, Chou JF, Dukleska K, Capanu M, Coit DG, Brennan MF, Strong VE.

Ann Surg Oncol. 2015 Oct;22(11):3590-6. doi: 10.1245/s10434-015-4381-y. Epub 2015 Jan 29.

42.

Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients.

Yaeger R, Cercek A, O'Reilly EM, Reidy DL, Kemeny N, Wolinsky T, Capanu M, Gollub MJ, Rosen N, Berger MF, Lacouture ME, Vakiani E, Saltz LB.

Clin Cancer Res. 2015 Mar 15;21(6):1313-20. doi: 10.1158/1078-0432.CCR-14-2779. Epub 2015 Jan 14.

43.

False discovery rates for rare variants from sequenced data.

Capanu M, Seshan VE.

Genet Epidemiol. 2015 Feb;39(2):65-76. doi: 10.1002/gepi.21880. Epub 2014 Dec 30.

44.

Identification of rare causal variants in sequence-based studies: methods and applications to VPS13B, a gene involved in Cohen syndrome and autism.

Ionita-Laza I, Capanu M, De Rubeis S, McCallum K, Buxbaum JD.

PLoS Genet. 2014 Dec 11;10(12):e1004729. doi: 10.1371/journal.pgen.1004729. eCollection 2014 Dec.

45.

RAS mutations affect pattern of metastatic spread and increase propensity for brain metastasis in colorectal cancer.

Yaeger R, Cowell E, Chou JF, Gewirtz AN, Borsu L, Vakiani E, Solit DB, Rosen N, Capanu M, Ladanyi M, Kemeny N.

Cancer. 2015 Apr 15;121(8):1195-203. doi: 10.1002/cncr.29196. Epub 2014 Dec 9.

46.

30-day-or-sooner readmissions of gastrointestinal medical oncology patients following cancer center inpatient service discharge: characteristics and preventability.

Epstein AS, Crosbie C, Martin SC, Egan B, Goring TN, Koo DJ, Kumar CB, Salvit C, Capanu M, Chou J, Saltz LB.

Hosp Pract (1995). 2014 Dec;42(5):34-44. doi: 10.3810/hp.2014.12.1157.

PMID:
25485916
47.

Ganetespib, a novel Hsp90 inhibitor in patients with KRAS mutated and wild type, refractory metastatic colorectal cancer.

Cercek A, Shia J, Gollub M, Chou JF, Capanu M, Raasch P, Reidy-Lagunes D, Proia DA, Vakiani E, Solit DB, Saltz LB.

Clin Colorectal Cancer. 2014 Dec;13(4):207-12. doi: 10.1016/j.clcc.2014.09.001. Epub 2014 Sep 21.

48.

KRAS mutation influences recurrence patterns in patients undergoing hepatic resection of colorectal metastases.

Kemeny NE, Chou JF, Capanu M, Gewirtz AN, Cercek A, Kingham TP, Jarnagin WR, Fong YC, DeMatteo RP, Allen PJ, Shia J, Ang C, Vakiani E, D'Angelica MI.

Cancer. 2014 Dec 15;120(24):3965-71. doi: 10.1002/cncr.28954. Epub 2014 Aug 25.

49.

A single-arm, nonrandomized phase II trial of neoadjuvant gemcitabine and oxaliplatin in patients with resectable pancreas adenocarcinoma.

OʼReilly EM, Perelshteyn A, Jarnagin WR, Schattner M, Gerdes H, Capanu M, Tang LH, LaValle J, Winston C, DeMatteo RP, DʼAngelica M, Kurtz RC, Abou-Alfa GK, Klimstra DS, Lowery MA, Brennan MF, Coit DG, Reidy DL, Kingham TP, Allen PJ.

Ann Surg. 2014 Jul;260(1):142-8. doi: 10.1097/SLA.0000000000000251.

50.

BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer.

Yaeger R, Cercek A, Chou JF, Sylvester BE, Kemeny NE, Hechtman JF, Ladanyi M, Rosen N, Weiser MR, Capanu M, Solit DB, D'Angelica MI, Vakiani E, Saltz LB.

Cancer. 2014 Aug 1;120(15):2316-24. doi: 10.1002/cncr.28729. Epub 2014 Apr 15.

Supplemental Content

Loading ...
Support Center